Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Tuberculosis research takes off


Scientists call for a global strategy for the development of new tuberculosis vaccines

For 80 years there was essentially a lull in tuberculosis research. Indeed, the last scientific breakthrough in 1921, the Bacillus Calmette-Guérin (BCG) vaccine, still forms the central pillar of tuberculosis prevention.

The tuberculosis bacterium Mycobacterium tuberculosis.

© MPI for Infection Biology / Volker Brinkmann

In most cases, immunisation with BCG protects children from the worst forms of the disease, but not against the most common form, pulmonary tuberculosis in adults and children.

The vaccine has therefore not helped to reduce the number of tuberculosis cases. Only since the start of the new millennium has research once again been able to report significant advances in the development of new vaccines and drugs.

There are now a number of promising vaccine candidates. But setbacks still occur: In 2013 the most advanced candidate proved disappointing in a clinical trial with children and in 2015 in a clinical trial with HIV-positive adults. Although several other candidates have passed preliminary clinical tests, BCG will remain the only available vaccine for some years to come.

At the same time, more and more cases of tuberculosis are occurring that are resistant to all drugs currently available. It therefore appears unlikely that the targets set by the World Health Organization (WHO) will be met, namely to reduce the global incidence of tuberculosis by 90 percent and the mortality rate by 95 percent by 2035. “The relentless rise in the number of tuberculosis cases appears to have been halted for the time being, and the incidence of tuberculosis is on a slow decline for the first time in decades. Nevertheless, we need to do a lot more to effectively contain the disease,” says Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin and member of several international research networks.

A major obstacle is the enormous cost of tuberculosis research. Even a phase 2 trial, which aims to evaluate efficacy and safety in a relatively few number of patients, costs about 20 million US dollars to run. A large-scale phase 3 trial costs a whopping 100 million dollars. Above and beyond that, ongoing tuberculosis research requires more than 100 million dollars per year. Yet the research and development costs for tuberculosis vaccines pale in significance compared to the financial burden imposed by the disease. According to a study, tuberculosis-related work incapacity and treatment costs the EU five billion euros every year. “We can only meet this financial challenge if public research organizations, industry, governments and non-governmental organizations join forces. At the same time, we need to do everything possible to make research more efficient,” says Kaufmann.

Together with Thomas G. Evans of Aeras and Willem A. Hanekom of the Bill & Melinda Gates Foundation, Kaufman proposes a number of measures for organising tuberculosis research more effectively in future. For example, it must be ensured that only the most promising vaccine candidates progress into subsequent trials. To this end, research institutes around the world must work closely together to coordinate their trials. For instance, they should define standardised targets for trials, compare vaccine candidates directly with each other in trials and establish exact criteria for measuring the protective effect of a vaccine. “In this way substantial costs could be saved. It would also be helpful to harmonise trials on tuberculosis vaccines with trials on tuberculosis drugs and HIV vaccines,” Kaufmann advises.

Considerable costs could also be saved if a way could be found to reduce the number of participants required for trials. One solution might be to conduct trials with subjects from high-risk groups. Individuals from such groups have a higher-than-average likelihood of becoming infected. Thus, the number of patients needed for informative trials could be recruited more quickly.

In addition, molecular tests such as the interferon gamma assay and the tuberculin skin test, which reliably demonstrate tuberculosis infection, could reduce the scope of trials and save money. Trials that measure the efficacy of vaccine candidates on the basis of such tests need fewer subjects. So-called biomarkers could also help identify those individuals in whom a vaccine is effective.

Moreover, the analysis of interim results of ongoing trials can improve their cost-efficiency. In this way, the trials can be quickly adjusted to take into account any new findings obtained, and the number of participants can be increased or reduced accordingly. “Other researchers should also have access to the data and samples from such trials so that future trials can also benefit from them,” says Kaufmann.


Prof. Dr. Dr. h. c. Stefan H.E. Kaufmann
Max Planck Institute for Infection Biology, Berlin
Phone: +49 30 28460-500

Fax: +49 30 28460-501


Original publication
Stefan H.E. Kaufmann, Thomas G. Evans, Willem A. Hanekom

Tuberculosis vaccines: Time for a global strategy

Science Translational Medicine, 25. Februar 2015


Prof. Dr. Dr. h. c. Stefan H.E. Kaufmann | Max Planck Institute for Infection Biology, Berlin
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>